Bicara Therapeutics (BCAX) Operating Leases (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Operating Leases data on file, last reported at $301000.0 in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $301000.0; the trailing twelve-month figure through Mar 2026 stood at $301000.0 (changed N/A YoY), and the FY2025 full-year result was $593000.0, up 352.67% from the prior year.
• Operating Leases for Q1 2026 stood at $301000.0, down from $593000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $1.2 million in Q2 2025 and bottomed at $131000.0 in Q4 2024.
• The 4-year median for Operating Leases is $372000.0 (2023), against an average of $511142.9.
• The widest annual swing landed in 2024, when Operating Leases tumbled 64.78%; it then soared 542.34% in 2025.
• A 4-year view of Operating Leases shows it stood at $372000.0 in 2023, then sank by 64.78% to $131000.0 in 2024, then jumped by 352.67% to $593000.0 in 2025, then slumped by 49.24% to $301000.0 in 2026.
• The last three Operating Leases figures came in at $301000.0 (Q1 2026), $593000.0 (Q4 2025), and $880000.0 (Q3 2025), per Business Quant data.

Peer Comparison